title: Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.
abstract: Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.
authors.forename: D
authors.initials: D
authors.lastname: Firinu
authors.forename: M P
authors.initials: MP
authors.lastname: Barca
authors.forename: L
authors.initials: L
authors.lastname: Serusi
authors.forename: M M
authors.initials: MM
authors.lastname: Lorrai
authors.forename: M M
authors.initials: MM
authors.lastname: Peralta
authors.forename: P E
authors.initials: PE
authors.lastname: Manconi
authors.forename: S R
authors.initials: SR
authors.lastname: Del Giacco
mesh_terms: D000368:Aged; D054179:Angioedemas, Hereditary / Q000188:drug therapy*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D065094:Bradykinin B2 Receptor Antagonists; D050718:Complement C1 Inhibitor Protein / Q000032:analysis / Q000627:therapeutic use; D005260:Female; D006801:Humans
chemical_list: D065094:Bradykinin B2 Receptor Antagonists; D050718:Complement C1 Inhibitor Protein; C065679:icatibant; D001920:Bradykinin